Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi PharmaphorumThe FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.NeuroscienceRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum The FDA has cleared Eisai and Biogen’s Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellares and Sonoma partner to automate cell therapy manufacturingNext: Novartis and Chai Discovery collaborate on antibody identification Related Stories Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026 Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026
